NP-6A: A FAMILY OF PEPTIDE THERAPEUTICS

  • Cardioprotective in Animal Studies

  • Less than 1KDa in Molecular Weight

  • Specifically activates the AT2R

info@novopyxis.com

  • We use knot theory

    to predict uncrystallized transmembrane protein structures

  • Our proprietary algorithms

    allow us to design de novo peptide drugs

  • Our academic partners

    inform our drug design and test our therapeutic candidates

PUBLICATIONS

Differential Effects of β-Blockers, Angiotensin II Receptor Blockers, and a Novel AT2R Agonist NP-6A4 on Stress Response of Nutrient-Starved Cardiovascular Cells (PLOS One, Mahmood et. al.)

Improvement of Cardiovascular Outcomes in Diabetic Rats by a Novel Angiotensin II Receptor Peptide Agonist (Hypertension, Pulakat et. al.)

Nutrient Stress Response of Cardiovascular Cells to β-Blockers, ARB and AT2R Agonists (Hypertension, Mahmood et. al.)

Regulation of Neuroprotective Myeloid Cell Leukemia 1 by Rapamycin and AT2R Agonists in Dopaminergic Neuronal Cell-line (Hypertension, Bajwa et. al.)